Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS

Exclusion Criteria

• •1. Subject undergoing any of the following treatments: azacitidine, decitabine, venetoclax, cytotoxic chemotherapy, radiotherapy, arsenic trioxide, interferon or interleukin.
• •2. High or very high IPSS-R risk category.
• •3. Subject diagnosed with any active neoplasm except:
• •* epidermoid or basal cell carcinoma,
• •* carcinoma in situ of the uterine cervix
• •* Carcinoma in situ of the breast
• •4. Subjects with a score on the New York Heart Association Scale IV.
• •5. Subjects with major surgery within 8 weeks prior to study inclusion. Subjects must have fully recovered from any previous surgery prior to inclusion in the study.
• •6. Subject with known clinically significant anaemia due to iron, vitamin B12 or folate deficiencies or autoimmune or hereditary haemolytic anaemia or uncontrolled hypothyroidism or known clinically significant haemorrhage or sequestration or subject with drug induced anaemia.
• •7. New onset or uncontrolled seizures.
• •8. Subjects with uncontrolled systemic fungal, bacterial or viral infections (defined as ongoing signs or symptoms related to the infection without improvement despite appropriate antibiotics or antimicrobial therapy).
• •9. Pregnant or breastfeeding women.
• •10. The subject has any condition, including the presence of laboratory abnormalities that would place the subject at unacceptable risk if he/she were to participate in the study.
• •11. The subject has any condition or receives concomitant medication that confounds the ability to interpret the study data.